In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
Niccoli, G., Andreotti, F., Marzo, F., Cecchetti, S., Santucci, E., D'Amario, D., Pafundi, T., Cosentino, N., Crea, F., Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction, <<EUROPEAN JOURNAL OF CLINICAL INVESTIGATION>>, 2011; 41 (11): 1210-1219. [doi:10.1111/j.1365-2362.2011.02528.x] [http://hdl.handle.net/10807/4260]
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction
Niccoli, Giampaolo;Andreotti, Felicita;Marzo, Francesca;Cecchetti, Silvia;Santucci, Eleonora;D'Amario, Domenico;Cosentino, Nicola;Crea, Filippo
2011
Abstract
In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
